RNA 치료제 및 RNA 백신 시장 : 모달리티별, 분자 유형별, 치료 영역별, 투여 경로별, 주요 지역별, 주요 기업별 - 업계 동향과 세계 예측(- 2035년)
RNA Therapeutics and RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players: Industry Trends and Global Forecasts, Till 2035
상품코드 : 1682714
리서치사 : Roots Analysis
발행일 : 2025년 03월
페이지 정보 : 영문 170 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,799 ₩ 6,940,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,999 ₩ 10,122,000
PDF (One-Location Site License) help
PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,599 ₩ 15,329,000
PDF (Department License) help
PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 17,999 ₩ 26,031,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계 RNA 치료제 및 RNA 백신 시장 규모는 2035년까지 68%의 연평균 복합 성장률(CAGR)로 확대되어 9억 4,000만 달러 규모로 성장할 것으로 예상됩니다.

인체의 단백질 생산과 유전자 기능 조절에 있어 RNA의 중요한 역할로 인해 RNA는 잠재적인 치료 수단으로 연구되고 있습니다. 연구자들은 이전에는 치료가 불가능하다고 여겨졌던 질병을 특이적으로 표적화하여 치료할 수 있다는 점에서 RNA 기반 의약품과 관련된 큰 잠재력을 발견하고 있습니다. 그러나 이러한 분자는 매우 불안정하기 때문에 치료법으로 적용하기에는 큰 저항이 있습니다. 최근 첨단 기술과 플랫폼의 등장으로 업계 관계자들의 관심은 안정성이 높고 비교적 낮은 용량으로 효과가 지속될 수 있는 개량형 RNA 기반 치료제로 옮겨가고 있습니다. 이러한 개량형 RNA 기반 치료제는 차세대 치료제로 불리며, 향후 10년간 빠르게 발전하여 차세대 주요 치료 접근법이 될 것으로 예상되며, RNA 치료제 및 백신 시장은 연구개발 노력, 투자 활동의 활성화, 유력 기업의 진입 증가에 힘입어 향후 큰 성장이 예상됩니다.

100개 이상의 차세대 RNA 치료제와 백신이 개발되어 다양한 치료 적응증에 대한 저용량 치료제를 제공합니다. 차세대 치료제의 75%는 주로 감염성 질환을 타겟으로 하는 신약개발 및 전임상 단계에 있으며, 업계는 차세대 치료제 포트폴리오를 적극적으로 추진하고 있습니다.

RNA Therapeutics and RNA Vaccines Market-IMG1

이러한 기술의 대부분은 세포 내 특정 부위에 표적 치료제의 전달을 촉진하는 것으로, RNA 치료제와 백신에 초점을 맞춘 대부분의 임상시험이 2022년에 등록되었습니다. 이들 임상시험의 70% 이상이 다양한 장소에서 완료되었거나 현재 환자를 모집하고 있습니다. 차세대 RNA 치료제 및 백신 관련 특허는 이 분야에서 창출된 지적 재산을 보호하기 위해 업계 내/외부 기업별로 1,170건에 가까운 특허가 출원/출원되었습니다. 이 시장에서 체결된 거래의 약 70%는 saRNA 치료제/백신 임상연구에 초점을 맞추고 있으며, 그 중 60% 이상의 파트너십이 감염성 질환 치료를 위해 체결되고 있습니다. 최근 몇 년동안 진행된 파트너십 및 자금 지원을 포함하여 차세대 RNA 치료제/백신에 초점을 맞춘 이니셔티브의 수가 증가함에 따라 주요 제약사들의 관심이 높아진 것을 알 수 있습니다. 차세대 RNA 치료제/백신 관련 시장 기회는 2026년부터 2035년까지 연평균 50% 이상 성장할 것으로 예상됩니다.

RNA Therapeutics and RNA Vaccines Market-IMG2

세계의 RNA 치료제 및 RNA 백신 시장에 대해 조사했으며, 시장 개요와 함께 양식별/분자 유형별/치료 영역별/투여 경로별/주요 지역별, 주요 기업별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 시장 구도

제7장 기술 상황

제8장 약제 개요

제9장 임상시험 분석

제10장 특허 분석

제11장 파트너십 및 협업

제12장 자금조달과 투자 분석

제13장 대형 제약회사의 이니셔티브

제14장 RNA 치료제 및 RNA 백신 시장 전체(-2035년)

제15장 RNA 치료제 및 RNA 백신 시장 전체, 모달리티별

제16장 RNA 치료제 및 RNA 백신 시장 전체, 분자 유형별

제17장 RNA 치료제 및 RNA 백신 시장 전체, 치료 영역별

제18장 RNA 치료제 및 RNA 백신 시장 전체, 투여 경로별

제19장 RNA 치료제 및 RNA 백신 시장 전체, 주요 지역별

제20장 RNA 치료제 및 RNA 백신 시장 전체, 주요 기업별

제21장 결론

제22장 부록 1 : 표 형식 데이터

제23장 부록 2 : 기업 및 단체 리스트

LSH
영문 목차

영문목차

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: OVERVIEW

As per Roots Analysis, the global RNA therapeutics market and RNA vaccines market is estimated to grow to USD 940 million by 2035, at a CAGR of 68% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Modality

Type of Molecule

Therapeutic Areas

Route of Administration

Key Geographical Regions

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: GROWTH AND TRENDS

Given the critical role it plays in producing proteins and regulating gene function in the human body, RNA is being investigated as a potential therapeutic modality. Researchers are realizing the vast potential associated with RNA-based drugs, given their ability to specifically target and treat diseases that earlier deemed untreatable. However, the highly unstable nature of such molecules offers significant resistance to their applicability as treatment options. In recent years, the advent of advanced technologies and platforms has escalated the interest of industry stakeholders towards enhanced and modified RNA-based therapies, that are believed to be highly stable and have an extended impact at relatively low doses. This class of modified RNA-based therapies is termed as next generation therapies, which are anticipated to evolve rapidly to become the next big therapeutic approach in the coming decade. Driven by the research and development efforts, high investment activity and increased involvement of prominent players, the RNA therapeutics and vaccines market is anticipated to witness significant growth in the foreseen future.

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY INSIGHTS

The report delves into the current state of the RNA therapeutics and RNA vaccines market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications.

2. 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio.

3. Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines.

RNA Therapeutics and RNA Vaccines Market - IMG1

4. Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell.

5. Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations.

6. Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field.

7. Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases.

8. Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 Billion across various funding rounds in the past four years.

9. The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years.

10. The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of more than 50% between 2026 to 2035.

RNA Therapeutics and RNA Vaccines Market - IMG2

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY SEGMENTS

Vaccines Account for the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the type of modality, the market is segmented into RNA therapeutics and RNA vaccines. At present, RNA vaccines capture a substantial proportion of the RNA therapeutics and RNA vaccines market. This trend is unlikely to change in the near future.

repRNA Dominates the RNA Therapeutics and RNA Vaccines Market During the Forecast Period

Based on the type of molecule, the market is segmented into replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA. At present, replicating RNA holds the maximum share of the the RNA therapeutics and RNA vaccines market. However, self amplifying RNA is likely to drive the market in the near future.

Infectious Diseases Segment Captures the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the therapeutic area, the market is segmented into infectious diseases and oncological disorders. Currently, infectious diseases account for the 100% share of the RNA therapeutics and RNA vaccines market. However, oncological disorders segment is likely to drive the market in the near future.

Intradermal Route Occupies for the Largest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the route of administration, the market is segmented into intradermal, intramuscular and intravenous. Currently, the intradermal route holds the majority share of the RNA therapeutics and RNA vaccines market. However, the intramuscular route is likely to drive the market in the near future.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Asia-Pacific. The majority of the share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in North America is expected to grow at a higher CAGR.

Example Players in the RNA Therapeutics and RNA Vaccines Market

RNA THERAPEUTICS AND RNA VACCINES MARKET: RESEARCH COVERAGE

Partnerships and Collaborations: An analysis of partnerships established in this sector based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] focus of partnership, [E] purpose of partnership, [F] therapeutic area, [G] most active players (in terms of number of partnerships) and [H] the regional distribution of partnership activity in this market.

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE

7. TECHNOLOGY LANDSCAPE

8. DRUG PROFILES

9. CLINICAL TRIAL ANALYSIS

10. PATENT ANALYSIS

11. PARTNERSHIPS AND COLLABORATIONS

12. FUNDING AND INVESTMENT ANALYSIS

13. BIG PHARMA INITIATIVES

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, till 2035

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

21. CONCLUSION

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기